Dominic Reynolds
Company: Remix Therapeutics
Job title: Chief Scientific Officer
Bio:
As Chief Scientific Officer, Dominic is stoked to be a part of building Remix from the ground up, leading the design and synthesis of compounds to reprogram RNA processing and forge a path to the clinic. Dominic has extensive experience in the biotech space and building successful biotech companies. Recent positions include drug discovery consultancy to two seed-stage companies at Third Rock Ventures and VP, Head of Chemistry at H3 Biomedicine, a company he joined on day one. Prior to that Dominic worked at Forma Therapeutics, where he also joined on the first day, and he started his career at Millennium Pharmaceuticals. He received his PhD in synthetic chemistry from the University of Cambridge and conducted postdoctoral training at Harvard University where he focused on natural product synthesis.
Seminars:
Drugging RNA–Protein Complexes with Small Molecules to Enable RNA Splice Modulation & Degradation 9:30 am
• REM-422 is being developed by Remix Therapeutics for the treatment of ACC and AML/HRMDS • REMaster™ platform identifies compounds that address undruggable high unmet medical need targets • Next generation Remix drug discovery programs are enabled by a suite of biophysical assays and expand the scope of pharmacologically tractable splice modulator modalitiesRead more
day: Conference Day One
Panel Discussion Increasing Chemical Diversity in RNA-Targeted Splice Modulator Small Molecules to Expand the Target Space & Address Previously Undruggable Diseases 1:00 pm
• How can expanding the target space beyond the common splice modulators unlock new opportunities for targeting novel disease areas • What strategies are enabling the design of chemically diverse scaffolds to overcome current limitations in the ligand design space • Are we overdependent on nonsense-mediated decay and can reducing this reliance drive broaden therapeutic…Read more
day: Conference Day One